HSBC has maintained a buy rating on Glenmark Pharmaceuticals, with a target price of ₹1,720, implying a potential upside of nearly 24% from the current market price of ₹1,389.20.
The brokerage acknowledged an operational miss in Q4 FY25, with one-off items impacting the company’s reported profit. However, HSBC believes the worst may be behind for Glenmark’s core geographies.
According to the note, the India and US businesses—which together contribute 56% of FY25 sales—appear to have bottomed out, and a growth rebound is anticipated in the coming quarters. HSBC remains optimistic about the company’s trajectory and believes that a potential outlicensing deal for ISB 2001 could act as a major re-rating catalyst for the stock.
The company’s recent efforts to streamline operations, sharpen focus on key geographies, and monetize pipeline assets are seen as positives for long-term investors.
Disclaimer: This article is for informational purposes only and is based solely on brokerage reports and publicly available data. It does not constitute investment advice or a recommendation to buy or sell any securities. Readers are advised to consult a certified financial advisor before making any investment decisions.
